IL-17 vs. IL-23 Inhibition in PsA: Dr. Philip Mease Discusses the Head-to-Head BE BOLD Trial Results

Bimekizumab (Bimzelx, UCB) bested risankizumab (Skyrizi, AbbVie) in achieving American College of Rheumatology 50 (ACR50) responses at Week 24 in patients with active psoriatic arthritis (PsA), according to results from the BE BOLD trial presented at ACR Convergence 2026 in Orlando, FL.